Exchange: NASDAQ·Updated 07:41 PM EST
MDXG logo

MDXG Mimedx Group Inc

$3.00
$0.06
(1.93%)
Today
Closed $3.05
$0.05
(1.64%)
After Hours
Reported EarningsOct 28
Mkt Cap$445.07M
Vol2.12M

About MDXG

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.
45

Neutral Sentiment

How do you feel about MDXG?

Omstapocus
$MDXG I think the best way to look at MDXG is the following : FTC second request not death kneel.Approval is more the norm ie Speed bump.Sanara third quarter revenue PLUS MDXG forcast $375M+ year end revenue,significant cash in the bank and consistent 20% EBITHA! No indication CMS will increase reimbursement so ?? there will be growth in that area. Conversion to “surgical company“ great BUT no articulation regarding product pipeline for clinical problems .Sanara does addresses specific products like bone and infection control that address surgical. With lack of any pipeline plan ,future mature stand alone surgical company doubtful M&A most likely.Sooner than later seems most likely. It would seem more robust and targeted clinical opportunities amenable to dHACM prophylaxis and repair would make M&A more attractive and to shareholder $$$ benefit. My guess Sanara acquisition … For Sale Sign. We actually may get out of this nightmare!
4
77HighStreet
$MDXG Cantor Fitzgerald analyst reiterated a Buy rating on MiMedx Group on November 13 and set a price target of $8.00. The company’s shares closed last Friday at $3.21. MiMedx Group has an analyst consensus of Strong Buy, with a price target consensus of $7.25, representing a 125.86% upside. In a report released on October 29, Craig-Hallum also maintained a Buy rating on the stock with a $7.00 price target. -TipRanks Newsdesk Nov 16, 2026, 08:35 AM
3
biomaster22
$MDXG what a joke it was all it will be ok on the cc call snd its plummeting to 52 week lows -get out crapper you failed shareholders no excuses
2
Raiderdave98
$MDXG 3 near term catalysts. Deal closure, Medicare pricing change, and now lawsuit settlements.
2
WarrenDouglasTrader
$MDXG Mdxg middle of guidance (275m), at 5X multiple (low end for surgical), places mkt cap at more than double current mkt cap. If deal happens, 400m estimate, at 5X multiple, quadruples current mkt cap.
2
WarrenDouglasTrader
$MDXG Well, its been 30+ days since FTC asked for more info.....question is when Mimedx and Sanara complied.
1
njbugatti
$MDXG anyone have any insight into potential recoveries from other two patent lawsuits? Capper said they were larger ongoing litigations. Sure would be a pleasant surprise to settle and receive $50-$100MM more in damages from competitors who violated our patents! Damages aka license agreements.
1
WarrenDouglasTrader
$MDXG I listened to the Cannacord presentation. The main point of emphasis was on the "pending Sanara acquisition". He used zero cautionary language----which was a surprise. What does he know????
Raiderdave98
$MDXG doing a search on second requests from the FTC is disheartening. Stock priced as deal not happening.
StocktwitsEarnings
$MDXG Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.01 down -106.67% YoY • Reported revenue of $62.28M down -45.23% YoY • MiMedx expects 2026 net sales of $250 to $260M, fourth-quarter Adjusted EBITDA sequentially higher than the third quarter, and longer-term annual net sales growth in the low double-digits with adjusted EBITDA margin above 20%.
shoc24
$MDXG reports earnings today after the close. I used Stock Meadow’s earnings dashboard to review its history: MDXG has beaten EPS estimates in 5 of its last 8 reports. What are you watching for?
shoc24
$MDXG reports earnings tomorrow after the close. I used Stock Meadow’s earnings dashboard to review its history: MDXG has beaten EPS estimates in 5 of its last 8 reports. Analysts expect EPS of $0.00. What are you watching for?

Advertisement|Remove ads.